Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Immupharma files international patent application for P140 precision medicine
Immupharma has filed a PCT application for its P140 approach to identify and treat patients with the so-called type-M immune profile. The application builds on a UK patent (priority Aug/Sep 2025) and includes additional experimental data generated during the 12-month priority period. The international phase includes search and publication and enables the pursuit of national/regional patent rights in selected markets. The company names P140 as a central value driver and aims to conclude a commercial agreement in 2026. » Más en de.investing.com
ImmuPharma selects Kymos Group as CRO for Kapiglucagon bioanalysis
ImmuPharma has chosen Kymos Deutschland/Prolytic through a competitive tender as the bioanalytical contract research partner for the Kapiglucagon program. Kymos will develop and validate regulated bioanalytical methods and analyse samples from nonclinical and phase 1 studies. Kapiglucagon is a glucagon prodrug intended for type 1 diabetes applications, aiming to improve solubility and formulation stability for dual-hormone artificial pancreas systems. The program is supported by recently awarded funding; Thermo Fisher is the CMC partner and Bachem is supplying the API, and a US regulatory pathway via 505(b)(2) is being explored. » Más en de.investing.com
ImmuPharma starts IND preparations for diabetes prodrug Kapiglucagon
ImmuPharma has initiated IND‑preparatory activities for Kapiglucagon, a glucagon prodrug for treating type 1 diabetes, and has engaged tranScrip Limited to prepare a regulatory strategy and a pre‑IND briefing for the FDA. The company is considering a 505(b)(2) approval pathway in the US, which could allow use of existing data on native glucagon. Kapiglucagon aims to address issues with native glucagon by providing improved solubility and formulation stability and could also be used in artificial pancreas systems. After the pre‑IND meeting, ImmuPharma plans to submit an IND and start first human studies; the program is supported by a recently approved financing initiative. » Más en de.investing.com
ImmuPharma launches retail offer to raise £1.5 million
ImmuPharma is offering private investors, via Winterflood Retail Access, 25 million new ordinary shares at 6.0 pence each to raise up to £1.5 million. A separate placing of around £7.5 million is running in parallel at the same price. The subscription period is expected to end on Friday, with a minimum subscription of £100; results are scheduled for 23 March 2026, and the issue is subject to shareholder approval and admission to trading on AIM. » Más en de.investing.com
ImmuPharma delays P140 partnership completion to 2026
ImmuPharma has postponed the planned closing of a partnership for its P140 autoimmune platform from the end of 2025 to 2026. The company is in talks with several potential partners, including some of the world’s ten largest pharmaceutical firms, and multiple confidentiality agreements have been signed. ImmuPharma says it is seeking the most suitable partner with a focus on long-term value creation; liquidity runway has been extended into the fourth quarter of 2026 through tax credits, option exercises and around £2m from a sharing agreement, and no further capital measures are planned. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -576,92 | 98,26 % |
| Beneficio neto | -5,46 M | 409,81 % |
| EBITDA | -1,24 M | 77,13 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 21,09 M € |
Número de acciones | 623,91 M |
Máximo/mínimo de 52 semanas | 0,13 € - 0,03 € |
| Dividendos | No |
Beta | 3,02 |
Ratio P/E | -2,26 |
Ratio PEG | 0,02 |
Ratio P/B | 8,66 |
Ratio P/S | 0,00 |
Perfil de la empresa
ImmuPharma plc, una empresa biofarmacéutica, descubre y desarrolla terapias basadas en péptidos. Sus terapias basadas en péptidos se utilizan en las áreas terapéuticas de autoinmunidad e inflamación, y de anti-infecciosos. El producto candidato principal de la compañía es Lupuzor, un inmunomodulador de autofagia, que se encuentra en ensayo clínico de fase III para el tratamiento del lupus, una enfermedad inflamatoria crónica autoinmune. Sus otros productos candidatos incluyen BioAMB, un fármaco basado en péptidos para el tratamiento de formulaciones de Anfotericina B, una infección fúngica causada por la familia de hongos Aspergillus; y BioCin, un fármaco antibacteriano basado en péptidos utilizado en casos de alta necesidad médica y como última línea de defensa. La compañía mantiene un acuerdo de colaboración con el Centre National de la Recherche Scientifique para el desarrollo de una plataforma tecnológica de péptidos para tratar la diabetes con agonistas del péptido similar al glucagón-1, así como para el desarrollo de péptidos como antagonistas del glucagón para tratar la diabetes tipo I y tipo II; y un acuerdo de licencia y desarrollo con Avion Pharmaceuticals LLC. ImmuPharma plc fue fundada en 1999 y tiene su sede en Londres, Reino Unido.
| Nombre | ImmuPharma |
| CEO | Timothy Paul McCarthy |
| Sede | London,
gl Reino Unido |
| Sitio web | |
| Salida a bolsa | 28/10/2003 |
| Empleados | 7 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
London Stock Exchange | IMM.L |
Frankfurt | 25I.F |
London | IMM.L |
München | 25I.MU |